1Xie S, Chang S, Yang P et al. Genetic contributions of nonautoimmune SWR mice toward lupus nephritis[J]. Immunol, 167 (12):7141-7149.
2Tsuchiya N, Kawasaki A, Tsao B P et al. Analysis of the association of HLA-DRB1, TNFalpha promoter and TNFR2(TNFRSF1B) polymorphism with SLE using transmission disequilibrium test[J]. Genes Immun,2001 ;2(6) :317-322.
3Lee E B, Yoo J E, Lee Y J et al. Tumor necrosis factor receptor 2 polymorphism in systemic lupus erythematosus: no association with disease[J]. Hum Immunol, 2001 ; 62(10) : 1148-1152.
4Seligman V A, suarez C, Lum R et al. The Fcgamma receptor Ⅲ A-158 Fallele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians[J]. Arthitis Rheum 2001;44(3):618-625.
5Zuniga R, Ng S, Peterson M G et al. Low-binding alleles of Fcgamma receptor types Ⅱ and Ⅲ A are inherited independently and are associated with systemic lupus erythematosus in Hispanic patients[J]. Arthritis Rheum,2001 ;44(2) :361-367.
6Yun H R, Koh H K et al. Fcgamma R Ⅱ A / Ⅲ A polymorphism and its association with clinical manifestation Korean lupus patients[J]. Lupus ,2001:10(7) :466-472.
7Haywood M E, Vyse T J, Kim S S et al. Autoantigen glycoprotein 70 expression regulated by a singleocus, which acts as checkpoint for pathogenic anti-glycoprotein 70 autoantibody production and hence for the corresponding develoment of severe nephritis, in lupus-prone BXSB mice[J].Immunol,2001 ; 167(3) : 1728-1733.
8Wang A Y, Poon P, Lai F M et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patient[ J].Kidney Int,2001 ;59(4) : 1520-1528.
9Liu Z H, Cheng Z H, Gong P T et al. Sex differences in estrogen receptor gene polymorphism and its association with lupus nephritis in Chinese [J]. Nephron,2002;90(2) : 174-180.
10Prkacin I, Novak B. Angiotensin-converting enzyme gene polymorphism in patients with systemic lupus[J]. Acta Med Croatica,2001 ;55(2) :72-76.
3Fanouriakis A, Krasoudaki E ,Tzanakakis M,et al. Recent progress in the treatment of lupus nephritis[ J ]. Mod Rheumatol, 2012,22 ( 6 ) : 803 - 813.
4Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis[J]. Kidney International,2010,77 (2) :152 -160.
5Houssiau FA, D'Cruz D, Sangle S,et al. Azathioprine versus mycophe- nolate mofetil for long - term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial [ J]. Ann Rheum Dis, 2010, 69 (12) :2083 - 2089.
6Dooley MA,Jayne D ,Ginzler EM ,et al. Mycophenolate versus azathio- prine as maintenance therapy for lupus nephritis [ J]. N Engl J Med, 2011,365 (20) :1886 - 1895.
7Bao H, Liu ZH, Xie HL,et al. Successful treatment of class V + IV lu-pus nephritis with multitarget therapy [ J]. J Am Soc Nephrol,2008, 19(10) :2001 -2010.
8Balow JE, Boumpas DT, Fessler BJ, et al. Management of lupus ne- phritis [ J ]. Kidney Int Suppl, 1996,53 : S88 - 92.
9Houssiau FA, Vaseoneelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis : the Euro - Lupus Nephritis Trial, a ran- domized trial of low - dose versus high - dose intravenous cyclophos- phamide [ J ]. Arthritis Rheum, 2002,46 ( 8 ) : 2121 - 2131.
10Sloan RP, Schwartz MM, Korbet SM, et al. Long- term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group [ J]. J Am Soc Nephrol, 1996,7 (2) :299 - 305.
